Protara Therapeutics, Inc.
- Last sale
- Oct 15, 2026 · -4.22%
- Market cap
- $143.02M
- 59.97M shares
- Filings
- 812
FY 2014
—Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−69.5% FY25 yoy
- $143.02M
- —
- —
- 1.0×
- -39.48%
- —
FY2025 figures · derived
Price
Oct 15, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2014 | 2014-12-31 | $2,948,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2023 | — | $91.00K | $91.00K | — | 11.43M sh | +1.1% | — |
| FY2022 | — | $90.00K | $90.00K | — | 11.31M sh | +0.5% | — |
| FY2021 | — | $228.00K | $228.00K | — | 11.25M sh | +0.2% | — |
Biological products, except diagnostic substances
Protara Therapeutics, Inc. is the 102nd largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
FATEFate Therapeutics Inc$6.6M51.2%2,051.1%$161.7MSTROSutro Biopharma, Inc.$102.5M65.2%186.5%$159.0MENGNenGene Therapeutics Inc.———$153.5MCMPXCompass Therapeutics, Inc.$0.0100.0%—$147.1M
TARAProtara Therapeutics, Inc. (this company)———$143.0M
ARMPArmata Pharmaceuticals, Inc.———$141.3MIPHAInnate Pharma SA———$140.6MMOLNMolecular Partners AG———$139.7MLENZLENZ Therapeutics, Inc.$19.1M—430.3%$127.9MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR